Essential (hemorrhagic) thrombocythemia
ICD-10 D47.3 is a billable code used to indicate a diagnosis of essential (hemorrhagic) thrombocythemia.
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an elevated platelet count, which can lead to both thrombotic and hemorrhagic complications. Patients with ET may present with symptoms such as headaches, dizziness, and an increased risk of bleeding due to dysfunctional platelets. The condition is classified as a neoplasm of uncertain behavior, meaning that while it is not classified as malignant, it has the potential for progression to more severe forms of myeloproliferative disorders or acute myeloid leukemia (AML). Diagnosis is typically confirmed through blood tests showing elevated platelet levels, bone marrow biopsy, and the presence of specific genetic mutations, such as JAK2 V617F. Surveillance is crucial for managing the risk of complications and monitoring for disease progression. Treatment options may include low-dose aspirin, cytoreductive therapy, and regular monitoring of blood counts. The management of ET requires a multidisciplinary approach, involving hematologists and primary care providers to ensure comprehensive care.
Detailed documentation of blood tests, symptoms, treatment plans, and follow-up care.
Patients presenting with elevated platelet counts, symptoms of thrombosis or hemorrhage, and those undergoing treatment for ET.
Ensure that all relevant laboratory results and treatment responses are documented to support coding.
Comprehensive patient history, including symptoms, family history, and any referrals to specialists.
Routine monitoring of patients with known ET and management of associated symptoms.
Documentation should reflect the ongoing management and any referrals to hematology for specialized care.
Used to monitor platelet counts in patients diagnosed with ET.
Document the reason for the CBC and any relevant clinical findings.
Hematologists may require more frequent monitoring compared to primary care.
The primary treatment for essential thrombocythemia often includes low-dose aspirin to reduce the risk of thrombotic events, along with cytoreductive therapy in high-risk patients to lower platelet counts.
